Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
Fig 7
Antitumor activity in endometrial PDX mouse xenograft models after treatment with ARQ 092 or ARQ 751.
An endometrial PDX mouse xenograft model, ARQ 092 dosed at 50, 75 or 100 mg/kg or ARQ 751 dosed at 25, 50, 75 mg/kg in a schedule of 5 days on and 2 days off for 20 days. (A) Plot of tumor growth inhibition. (B) Plot of tumor regrowth after removal of drug. (Day 20 to Day 40).